The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

Between 20 and 30 percent of people with psoriasis eventually develop a second, more disabling problem: painful joint ...

From prestige staples like Paul Mitchell's Tea Tree to drugstore darlings like Dove, these soothing shampoos promise to clean ...

As instances of scalp flaking increase and people scratch their heads in shame, dermatologists give some advice ...

Earning the 2025 Best of Georgia Award underscores Root Revival’s commitment to delivering results that are both visible and ...

New research suggests the scalps of people in London may need just as more attention as skin or fitness routines.

Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in. Eli Lilly and Company ...

Shampoo and conditioner recalled over banned chemical linked to fertility risks - The products were found to contain a ...

By Christy Santhosh Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, ...

Daily makeup can stress your skin and clog pores, but only if you use the wrong products and don’t remove makeup properly.

Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.